Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy. | Mayo Clin Proc Innov Qual Outcomes;6(5): 458-464, 2022 Oct. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

Brasil - Virtual Health Library

Information and Knowledge for Health

Subject descriptor lookup Advanced Search

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy.

Sridharan, Meera; Go, Ronald S; Willrich, Maria A V.

Affiliation

Sridharan M; Division of Hematology, Rochester, MN.
Go RS; Division of Hematology, Rochester, MN.
Willrich MAV; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Mayo Clin Proc Innov Qual Outcomes ; 6(5): 458-464, 2022 Oct.

Article in En | MEDLINE | ID: mdl-36160640

Key words

CM-TMA, complement-mediated thrombotic microangiopathy; DNP, dinitrophenyl; RI, reference interval; aHUS, atypical hemolytic uremic syndrome

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Mayo Clin Proc Innov Qual Outcomes Year: 2022 Document type: Article

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Mayo Clin Proc Innov Qual Outcomes Year: 2022 Document type: Article